4-(4-(HEXYLOXY)PHENYL)-3-(2-FLUOROPHENYL)-4H-1,2,4-TRIAZOLE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MSEYFTFNQVXTJX-UHFFFAOYSA-N
Smiles	CCCCCCOc1ccc(cc1)n2cnnc2c3ccccc3F
InChI	InChI=1S/C20H22FN3O/c1-2-3-4-7-14-25-17-12-10-16(11-13-17)24-15-22-23-20(24)18-8-5-6-9-19(18)21/h5-6,8-13,15H,2-4,7,14H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H22FN3O
Molecular Weight	339.41
AlogP	5.33
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	39.94
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	25.0

Assay Description	Organism	Bioactivity
Protective index, ratio of TD50 for neurotoxicity to ED50 for anticonvulsant activity in ip dosed Mus musculus C57B/6 (mouse)	Mus musculus	5.0
Neurotoxicity in ip dosed Mus musculus C57B/6 (mouse) assessed as inability to maintain equilibrium measured after 30 min by rotarod test	Mus musculus	101.0 mg kg-1
Anticonvulsant activity in ip dosed Mus musculus C57B/6 (mouse) assessed as protection against maximal electroshock-induced seizures	Mus musculus	20.2 mg.kg-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2262020
PubChem	76330268

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).